Modulation of anxiety through blockade of anandamide hydrolysis
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The psychoactive constituent of cannabis, Δ9-tetrahydrocannabinol, produces in humans subjective responses mediated by CB1 cannabinoid receptors, indicating that endogenous cannabinoids may contribute to the control of emotion. But the variable effects of Δ9-tetrahydrocannabinol obscure the interpretation of these results and limit the therapeutic potential of direct cannabinoid agonists. An alternative approach may be to develop drugs that amplify the effects of endogenous cannabinoids by preventing their inactivation. Here we describe a class of potent, selective and systemically active inhibitors of fatty acid amide hydrolase, the enzyme responsible for the degradation of the endogenous cannabinoid anandamide. Like clinically used anti-anxiety drugs, in rats the inhibitors exhibit benzodiazepine-like properties in the elevated zero-maze test and suppress isolation-induced vocalizations. These effects are accompanied by augmented brain levels of anandamide and are prevented by CB1 receptor blockade. Our results indicate that anandamide participates in the modulation of emotional states and point to fatty acid amide hydrolase inhibition as an innovative approach to anti-anxiety therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both serotonin and endocannabinoids are involved in stress-related phenotypes, such as anxiety (212).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“the endogenous cannabinoids, such as anandamide, sleep-inducing substance oleamide (211) and palmitoylethanolamide (212), regulate numerous biological processes such as neuronal migration (213), learning, memory (214), pain processing (215), motility (216), and emotional-and reward-related processing (217–219).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“Nabilone (Cesamet; Valeant Canada, Ltd., Montreal, Canada), an endocannabinoid receptor (CB 1 and CB 2 ) agonist, has been in use in Europe and Canada for over 25 years and was recently granted approval in the United States for the treatment of chemotherapy-induced nausea and vomiting.”
From The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD) (2009) · cites this paper as [12]
In the citing paper
“It has been well established that inhibition of FAAH, and elevation of AEA signaling, can significantly attenuate behavioral indices of fear and anxiety-related behavior in rodents.”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Kathuria et al., 2003
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Self-citationMechanisms of emotional arousal and lasting declarative memory.
Cahill, L., & McGaugh, J. L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01214-9 · Cited by 1,575
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Self-citationBrain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373
Self-citationCravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“Surprisingly, the use of cannabinoid receptor antagonists, including SR141716, AM281, AM251, and SR144528, also leads to survival benefits in endotoxic and septic shock or necrotizing pancreatitis (Varga et al., 1998; Smith et al., 2000, 2001; Cainazzo et al., 2002; Kadoi et al., 2005a,b; Matsuda et al., 2005).”
BackgroundInfluentialThe molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
Self-citationChronic stress, drug use, and vulnerability to addiction
Sinha, R. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1441.030 · Cited by 1,904
Role of Endogenous Cannabinoids in Synaptic Signaling
FREUND, T. F., KATONA, I., & PIOMELLI, D. (2003) · Physiological Reviews · doi:10.1152/physrev.00004.2003 · Cited by 1,574
“The pharmacological profile of URB597, which is currently under investigation, includes profound antianxiety effects accompanied by modest analgesia (185).”
BackgroundInfluentialSelf-citationNew approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Endocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,529
Activity-Based Protein Profiling: From Enzyme Chemistry to Proteomic Chemistry
Cravatt, B. F., Wright, A. T., & Kozarich, J. W. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.101304.124125 · Cited by 1,270
A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol
Blankman, J. L., Simon, G. M., & Cravatt, B. F. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.11.006 · Cited by 1,177
“Consistent with these previous studies, we observed selective blockade of FP-rhodamine labeling of FAAH and ABHD6 in brain-membrane proteomes treated with URB597 (10 mM) and WWL70 (10 mM), respectively (Figure 5A).”
BackgroundInfluentialThe endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090
“The Piomelli group (Kathuria et al. 2003) reported a novel class of potent, selective, and systemically active carbamatebased inhibitors of FAAH, the enzyme responsible for the degradation of anandamide.”
BackgroundThe endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects
Long, J. Z., Li, W., Booker, L., Burston, J. J., Kinsey, S. G., Schlosburg, J. E., Pavón, F. J., Serrano, A. M., Selley, D. E., Parsons, L. H., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.129 · Cited by 934
“Other MAGs, such as mono-palmitoylglycerol (14) (PG) and mono-oleoylglycerol (15) (OG), and their corresponding free fatty acids, palmitic (16) and oleic acid (17), respectively, were not significantly altered in brains from JZL184-treated animals (Supplementary Fig.”
BackgroundThe Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0009 · Cited by 865
“anxiety-like response in different tasks (147).”
BackgroundENDOCANNABINOID-MEDIATED SYNAPTIC PLASTICITY IN THE CNS
Chevaleyre, V., Takahashi, K. A., & Castillo, P. E. (2006) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.29.051605.112834 · Cited by 783
Targeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
An endocannabinoid mechanism for stress-induced analgesia
Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., Krey, J. F., Michael Walker, J., Holmes, P. V., Crystal, J. D., et al. (2005) · Nature · doi:10.1038/nature03658 · Cited by 778
Self-citationEndocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models
Kreitzer, A. C., & Malenka, R. C. (2007) · Nature · doi:10.1038/nature05506 · Cited by 735
Neurobiological Interactions Between Stress and the Endocannabinoid System
Morena, M., Patel, S., Bains, J. S., & Hill, M. N. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.166 · Cited by 660
“The putative role of AEA in regulating anxiety was first highlighted by the Piomelli laboratory, who demonstrated that inhibition of AEA-hydrolysis by FAAH resulted in a reduction of anxiety (Kathuria et al, 2003).”
BackgroundGobbi, G., Bambico, F. R., Mangieri, R., Bortolato, M., Campolongo, P., Solinas, M., Cassano, T., Morgese, M. G., Debonnel, G., Duranti, A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509591102 · Cited by 673
Self-citationThe endocannabinoid system links gut microbiota to adipogenesis
Muccioli, G. G., Naslain, D., Bäckhed, F., Reigstad, C. S., Lambert, D. M., Delzenne, N. M., & Cani, P. D. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.46 · Cited by 691
“Consistent with the results obtained using the cannabinoid receptor agonist, inhibition of AEA degradation by administration of a potent FAAH inhibitor, URB597 (Kathuria et al, 2003), significantly increased AEA levels (CT: 100±7.4%; URB597: 117.5±4.9; Po0.”
BackgroundResultInfluentialStructure and function of fatty acid amide hydrolase
McKinney, M. K., & Cravatt, B. F. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133450 · Cited by 680
Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system
Schlosburg, J. E., Blankman, J. L., Long, J. Z., Nomura, D. K., Pan, B., Kinsey, S. G., Nguyen, P. T., Ramesh, D., Booker, L., Burston, J. J., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2616 · Cited by 641
Endocannabinoid signaling as a synaptic circuit breaker in neurological disease
Katona, I., & Freund, T. F. (2008) · Nature Medicine · doi:10.1038/nm.f.1869 · Cited by 579
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system
Ahn, K., McKinney, M. K., & Cravatt, B. F. (2008) · Chemical Reviews · doi:10.1021/cr0782067 · Cited by 529
CANNABINOID RECEPTORS AS THERAPEUTIC TARGETS
Mackie, K. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141254 · Cited by 505
“The carbamate FAAH inhibitors are also efficacious in two anxiolysis models (140).”
BackgroundThe endocannabinoid system in guarding against fear, anxiety and stress
Lutz, B., Marsicano, G., Maldonado, R., & Hillard, C. J. (2015) · Nature reviews. Neuroscience · doi:10.1038/nrn4036 · Cited by 506
Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
“Accordingly, FAAH inhibitors produce anxiolytic-like effects in rats in a CB1-mediated manner (426).”
BackgroundA biosynthetic pathway for anandamide
Liu, J., Wang, L., Harvey-White, J., Osei-Hyiaman, D., Razdan, R., Gong, Q., Chan, A. C., Zhou, Z., Huang, B. X., Kim, H.-Y., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601832103 · Cited by 470
Patel, S., Roelke, C. T., Rademacher, D. J., Cullinan, W. E., & Hillard, C. J. (2004) · Endocrinology · doi:10.1210/en.2004-0638 · Cited by 475
“amide content (including AEA) (7), blocked restraint-”
BackgroundMethodInfluentialThe Endocannabinoid System and Pain
Guindon, J., & Hohmann, A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824660 · Cited by 476
“Consistent with this observation, FAAH inhibitors (URB597 and URB532) produce CB1-mediated antinociception [204].”
BackgroundThe endocannabinoid system: a general view and latest additions
Petrocellis, L. D., Cascio, M. G., & Marzo, V. D. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705666 · Cited by 475
“…et al., 2001; Ortar et al., 2003); FAAH inhibitors enhance, and anandamide uptake inhibitors inhibit, anandamide accumulation in cells (Kathuria et al., 2003); (3) substances that inhibit the AMT enhance the effect of AEA that are exerted at extracellular sites (i.e. at CB1 receptors)…”
BackgroundThe serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors
Marrs, W. R., Blankman, J. L., Horne, E. A., Thomazeau, A., Lin, Y. H., Coy, J., Bodor, A. L., Muccioli, G. G., Hu, S. S.-J., Woodruff, G., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2601 · Cited by 441
Pharmacological Profile of the Selective FAAH Inhibitor KDS-4103 (URB597)
Piomelli, D., Tarzia, G., Duranti, A., Tontini, A., Mor, M., Compton, T. R., Dasse, O., Monaghan, E. P., Parrott, J. A., & Putman, D. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00021.x · Cited by 441
“The effect of anandamide plus KDS-4103 is mediated by CB1 receptors, since it is prevented by the CB1 antagonist rimonabant (27).”
BackgroundMethodInfluentialSelf-citationDiscovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain
Ahn, K., Johnson, D. S., Mileni, M., Beidler, D., Long, J. Z., McKinney, M. K., Weerapana, E., Sadagopan, N., Liimatta, M., Smith, S. E., et al. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.02.013 · Cited by 439
“…hydrolase (FAAH) (Cravatt et al., 1996; McKinney and Cravatt, 2005) and FAAH(À/À) mice have been found to display analgesia (Cravatt et al., 2001; Kathuria et al., 2003; Lichtman et al., 2004a, 2004b; Chang et al., 2006; Russo et al., 2007), anti-inflammation (Cravatt et al., 2004; Massa et al.,…”
BackgroundResultInfluentialThe Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease
Long, J. Z., & Cravatt, B. F. (2011) · Chemical Reviews · doi:10.1021/cr200075y · Cited by 425
Fegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078980 · Cited by 427
“Furthermore, in agreement with prior results (Kathuria et al., 2003), the drug had no effect on the levels of 2-AG, another endocannabinoid ligand (Mechoulam et al., 1995; Sugiura et al., 1995; Stella et al., 1997) in either wild-type or FAAH / mice (data not shown).”
BackgroundResultInfluentialSelf-citationUrea Derivatives in Modern Drug Discovery and Medicinal Chemistry
Ghosh, A. K., & Brindisi, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01541 · Cited by 401
THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY
RODRÍGUEZ de FONSECA, F., DEL ARCO, I., BERMUDEZ-SILVA, F. J., BILBAO, A., CIPPITELLI, A., & NAVARRO, M. (2005) · Alcohol and Alcoholism · doi:10.1093/alcalc/agh110 · Cited by 407
“A different strategy has been selected by the group of Piomelli et al., who have developed exceptionally potent irreversible FAAH inhibitors, which exhibit a promising anxiolytic profile (Kathuria et al., 2003; Tarzia et al., 2003a).”
BackgroundMethodInfluentialModulating the endocannabinoid system in human health and disease – successes and failures
Pacher, P., & Kunos, G. (2013) · The FEBS Journal · doi:10.1111/febs.12260 · Cited by 405
“In support of this, FAAH knockout mice or mice treated with a FAAH inhibitor have elevated AEA levels in the brain and other tissues, are supersensitive to exogenous AEA and exhibit CB1 receptor-mediated hypoalgesia[160,161] and reduced anxiety, but do not display catalepsy, a marker for psychoactivity in humans[162].”
BackgroundGoodman, A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.030 · Cited by 413
Long, J. Z., Nomura, D. K., Vann, R. E., Walentiny, D. M., Booker, L., Jin, X., Burston, J. J., Sim-Selley, L. J., Lichtman, A. H., Wiley, J. L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909411106 · Cited by 391
“This finding is consistent with previous literature indicating that both AEA and 2-AG can independently regulate pain sensation (19, 20, 23, 26), and suggests further that their individual activities are profoundly augmented upon simultaneous blockade of their respective degradative enzymes.”
BackgroundResultLauffer, L. M., Iakoubov, R., & Brubaker, P. L. (2009) · Diabetes · doi:10.2337/db08-1237 · Cited by 399
“These findings indicate that degradation by FAAH limits the effects of OEA on GLP-1 secretion in both of the intestinal L-cell lines utilized.”
MethodInfluentialPatel, S., & Hillard, C. J. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.101287 · Cited by 392
“Specifically, brain AEA content is significantly increased by the FAAH inhibitor cyclohexyl carbamic acid 3 -carbamoyl-biphenyl-3-yl ester (URB597) (Kathuria et al., 2003).”
BackgroundResultInfluentialDiscovering potent and selective reversible inhibitors of enzymes in complex proteomes
Leung, D., Hardouin, C., Boger, D. L., & Cravatt, B. F. (2003) · Nature Biotechnology · doi:10.1038/nbt826 · Cited by 385
Enhancing Cannabinoid Neurotransmission Augments the Extinction of Conditioned Fear
Chhatwal, J. P., Davis, M., Maguschak, K. A., & Ressler, K. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300655 · Cited by 376
“Manipulation of the endogenous cannabinoid (eCB) system has become a major focus of current research, especially in the search for novel therapeutics to treat many common mental illnesses, including anxiety disorders, depression, and drug addiction (Porter and Felder, 2001; Kathuria et al, 2003).”
BackgroundResultHuggins, J. P., Smart, T. S., Langman, S., Taylor, L., & Young, T. (2012) · Pain · doi:10.1016/j.pain.2012.04.020 · Cited by 375
“This does not cause the overt untoward effects associated with exogenous compounds [3,6,11,16,27,32,33].”
BackgroundEnzyme Inhibitor Discovery by Activity-Based Protein Profiling
Niphakis, M. J., & Cravatt, B. F. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060713-035708 · Cited by 366
Iannotti, F. A., Di Marzo, V., & Petrosino, S. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.02.002 · Cited by 357
A Second Fatty Acid Amide Hydrolase with Variable Distribution among Placental Mammals
Wei, B. Q., Mikkelsen, T. S., McKinney, M. K., Lander, E. S., & Cravatt, B. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606646200 · Cited by 363
GABAA receptor diversity and pharmacology
Möhler, H. (2006) · Cell and Tissue Research · doi:10.1007/s00441-006-0284-3 · Cited by 363
“Pharmacologically, the inhibition of the degradation of anandamide resulted in an CB1 receptor-mediated anxiolytic response (Kathuria et al. 2003).”
BackgroundSimon, G. M., & Cravatt, B. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604660200 · Cited by 356
The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications
Lambert, D. M., & Fowler, C. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058183t · Cited by 350
Leung, D., Saghatelian, A., Simon, G. M., & Cravatt, B. F. (2006) · Biochemistry · doi:10.1021/bi060163l · Cited by 350
“in pain sensitivity ( 8-11), anxiety (12), and inflammation”
BackgroundThe therapeutic potential of cannabis
Baker, D., Pryce, G., Giovannoni, G., & Thompson, A. J. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00381-8 · Cited by 343
Endogenous cannabinoid signaling is essential for stress adaptation
Hill, M. N., McLaughlin, R. J., Bingham, B., Shrestha, L., Lee, T. T. Y., Gray, J. M., Hillard, C. J., Gorzalka, B. B., & Viau, V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914661107 · Cited by 349
“These pharmacological agents were used at doses sufficient to modulate endocannabinoid signaling (19, 20) but not to modulate HPA responses to acute stress exposure (SI Text and Fig.”
BackgroundBortolato, M., Mangieri, R. A., Fu, J., Kim, J. H., Arguello, O., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.001 · Cited by 347
“Thus, unlike 9-THC and other directacting cannabinoid receptor agonists (Lichtman and Martin 2005), URB597 appears to be devoid of significant abuse potential.”
BackgroundSelf-citationAnandamide suppresses pain initiation through a peripheral endocannabinoid mechanism
Clapper, J. R., Moreno-Sanz, G., Russo, R., Guijarro, A., Vacondio, F., Duranti, A., Tontini, A., Sanchini, S., Sciolino, N. R., Spradley, J. M., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2632 · Cited by 346
Self-citationGeurts, L., Lazarevic, V., Derrien, M., Everard, A., Van Roye, M., Knauf, C., Valet, P., Girard, M., Muccioli, G. G., François, P., et al. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00149 · Cited by 325
The endocannabinoid system drives neural progenitor proliferation
Aguado, T., Monory, K., Palazuelos, J., Stella‡, N., Cravatt, B., Lutz, B., Marsicano, G., Kokaia, Z., Guzmán, M., & Galve‐Roperh, I. (2005) · The FASEB Journal · doi:10.1096/fj.05-3995fje · Cited by 327
“URB597 and 2AG were from Cayman Chemicals, mouse monoclonal anti-nestin and rabbit polyclonal anti-FAAH antibodies from Chemicon, and rabbit monoclonal anti-Ki-67 (clone SP6) antibody from LabVision.”
InfluentialActivity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474
van Esbroeck, A. C. M., Janssen, A. P. A., Cognetta, A. B., Ogasawara, D., Shpak, G., van der Kroeg, M., Kantae, V., Baggelaar, M. P., de Vrij, F. M. S., Deng, H., et al. (2017) · Science · doi:10.1126/science.aaf7497 · Cited by 332
Lichtman, A. H., Leung, D., Shelton, C. C., Saghatelian, A., Hardouin, C., Boger, D. L., & Cravatt, B. F. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.069401 · Cited by 328
“…subset of the behavioral effects observed with CB1 agonists (Cravatt et al., at A SPE T Journals on February 7, 2021 jpet.aspetjournals.org D ow nloaded from JPET #69401 18 2001, Kathuria et al., 2003) and suggest a key role for the FAAH-endocannabinoid system in modulating multiple pain pathways.”
BackgroundInfluentialRadiopharmaceuticals and their applications in medicine
Zhang, S., Wang, X., Gao, X., Chen, X., Li, L., Li, G., Liu, C., Miao, Y., Wang, R., & Hu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02041-6 · Cited by 284
Cannabinoids, opioids and eating behavior: The molecular face of hedonism?
Cota, D., Tschöp, M. H., Horvath, T. L., & Levine, A. S. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2005.10.004 · Cited by 330
Blockade of Endocannabinoid-Degrading Enzymes Attenuates Neuropathic Pain
Kinsey, S. G., Long, J. Z., O’Neal, S. T., Abdullah, R. A., Poklis, J. L., Boger, D. L., Cravatt, B. F., & Lichtman, A. H. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.155465 · Cited by 330
Tsuboi, K., Sun, Y.-X., Okamoto, Y., Araki, N., Tonai, T., & Ueda, N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413473200 · Cited by 332
Chemical Probes of Endocannabinoid Metabolism
Blankman, J. L., & Cravatt, B. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006387 · Cited by 327
“Importantly, these effects occurred without altering motility, body temperature, or appetite (Kathuria et al., 2003).”
BackgroundLigands that target cannabinoid receptors in the brain: from THC to anandamide and beyond
Pertwee, R. G. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00108.x · Cited by 314
Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension
Bátkai, S., Pacher, P., Osei-Hyiaman, D., Radaeva, S., Liu, J., Harvey-White, J., Offertáler, L., Mackie, K., Rudd, M. A., Bukoski, R. D., et al. (2004) · Circulation · doi:10.1161/01.cir.0000143230.23252.d2 · Cited by 322
“Affinity purified CB1 polyclonal antibody was raised in rabbit against the first 100 amino acids of human CB1.”
BackgroundInfluentialEndocannabinoids: synthesis and degradation
Di Marzo, V. (2006) · Reviews of Physiology, Biochemistry and Pharmacology · doi:10.1007/112_0505 · Cited by 311
The pharmacological landscape and therapeutic potential of serine hydrolases
Bachovchin, D. A., & Cravatt, B. F. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3620 · Cited by 308
Campos, A. C., Ortega, Z., Palazuelos, J., Fogaça, M. V., Aguiar, D. C., Díaz-Alonso, J., Ortega-Gutiérrez, S., Vázquez-Villa, H., Moreira, F. A., Guzmán, M., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001502 · Cited by 313
“…degradation inhibitors promote hippocampal progenitor proliferation and neurogenesis (Aguado et al., 2007) and exert beneficial anxiolytic effects while being devoid of undesired CB 1 receptor-associated psychoactivity (Kathuria et al., 2003 ; Busquets-Garcia et al., 2011 ; Kinsey et al., 2011).”
BackgroundMultiple pathways involved in the biosynthesis of anandamide
Liu, J., Wang, L., Harvey-White, J., Huang, B. X., Kim, H.-Y., Luquet, S., Palmiter, R. D., Krystal, G., Rai, R., Mahadevan, A., et al. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.05.020 · Cited by 304
“N IH -PA Author M anuscript N IH -PA Author M anuscript enzymes that metabolize ECs were found to potentiate some but not other EC actions (Kathuria et al., 2003), which suggests that blocking EC biosynthesis may have a pharmacological profile different from that achieved by blocking cannabinoid…”
BackgroundGunduz-Cinar, O., MacPherson, K. P., Cinar, R., Gamble-George, J., Sugden, K., Williams, B., Godlewski, G., Ramikie, T. S., Gorka, A. X., Alapafuja, S. O., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.72 · Cited by 307
Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum
Maccarrone, M., Rossi, S., Bari, M., De Chiara, V., Fezza, F., Musella, A., Gasperi, V., Prosperetti, C., Bernardi, G., Finazzi-Agrò, A., et al. (2008) · Nature Neuroscience · doi:10.1038/nn2042 · Cited by 295
Hill, M. N., McLaughlin, R. J., Morrish, A. C., Viau, V., Floresco, S. B., Hillard, C. J., & Gorzalka, B. B. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.114 · Cited by 304
“Similarly, systemic administration of CB1 receptor agonists can enhance stress-induced HPA axis activation (Patel et al., 2004; Jacobs et al., 1979; Hill and Gorzalka, 2006).”
BackgroundFatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system
Cravatt, B. F., & Lichtman, A. H. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00079-6 · Cited by 302
Cannabinoid receptors and endocannabinoids: Evidence for new players
Mackie, K., & Stella, N. (2006) · The AAPS Journal · doi:10.1007/bf02854900 · Cited by 275
Lichtman, A. H., Shelton, C. C., Advani, T., & Cravatt, B. F. (2004) · Pain · doi:10.1016/j.pain.2004.01.022 · Cited by 301
“More recently, mice treated with irreversible FAAH inhibitors also exhibited significant CB1 receptor-dependent hypoalgesia in the mouse hot plate test (Kathuria et al., 2003).”
BackgroundPatel, S., Roelke, C. T., Rademacher, D. J., & Hillard, C. J. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03916.x · Cited by 297
“Taken together with recent data showing anxiolytic effects of eCB-potentiating compounds (Kathuria et al., 2003; Patel et al., 2004b), a role for eCB signalling in the extinction of fear memories (Marsicano et al.”
BackgroundInfluentialRole in Anxiety Behavior of the Endocannabinoid System in the Prefrontal Cortex
Rubino, T., Realini, N., Castiglioni, C., Guidali, C., Vigano, D., Marras, E., Petrosino, S., Perletti, G., Maccarrone, M., Di Marzo, V., et al. (2008) · Cerebral Cortex · doi:10.1093/cercor/bhm161 · Cited by 283
“As to the finding of increased 2-AG levels in mock- and, particularly, FAAH-transduced animals, this was surprising as previous reports have shown either no changes or increases following pharmacological FAAH ‘‘inactivation’’ in rats (Kathuria et al. 2003; De Lago et al. 2005; Maione et al. 2006).”
BackgroundResultEndocannabinoids and the regulation of their levels in health and disease
Di Marzo, V., & Petrosino, S. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32803dbdec · Cited by 289
van der Stelt, M., & Di Marzo, V. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.101 · Cited by 291
FAAH genetic variation enhances fronto-amygdala function in mouse and human
Dincheva, I., Drysdale, A. T., Hartley, C. A., Johnson, D. C., Jing, D., King, E. C., Ra, S., Gray, J. M., Yang, R., DeGruccio, A. M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7395 · Cited by 289
Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma
Jiang, S., Postovit, L., Cattaneo, A., Binder, E. B., & Aitchison, K. J. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00808 · Cited by 288
Moreira, F. A., Kaiser, N., Monory, K., & Lutz, B. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.005 · Cited by 281
“Consistent with our study, Kathuria et al. (2003) also showed that rimonabant blocked the anxiolytic effect induced by pharmacological inhibition of FAAH in rats, also pointing to an involvement of CB1 receptors in the anxiolytic.”
BackgroundMethodResultInfluentialActions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models
Jayamanne, A., Greenwood, R., Mitchell, V. A., Aslan, S., Piomelli, D., & Vaughan, C. W. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706510 · Cited by 287
Self-citationTanda, G., & Goldberg, S. R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1485-z · Cited by 277
The cannabinoid system and pain
Woodhams, S. G., Chapman, V., Finn, D. P., Hohmann, A. G., & Neugebauer, V. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.06.015 · Cited by 267
“…to the development of several classes of compounds capable of inhibiting FAAH and thus promoting signalling of AEA (PF3845 - Ahn et al., 2009; PF-04457845 - Ahn et al., 2011; OL135 - Chang et al., 2006; JNJ-1661010 - Karbarz et al., 2009; URB597 - Kathuria et al., 2003) and other fatty-acid amides.”
Supply and demand for endocannabinoids
Alger, B. E., & Kim, J. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.03.003 · Cited by 268
Fraser, G. A. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00071.x · Cited by 283
“The CB1 receptor is distributed primarily within the CNS, particularly in the cerebellum, basal ganglia, amygdala, cerebral cortex, and hippocampus [12,13].”
BackgroundEndocannabinoid signaling in microglial cells
Stella, N. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.037 · Cited by 272
“This selective accumulation of anandamide relieves signs of anxiety and depression in mice undergoing distress, and reduces inflammationinduced pain and autoimmune-mediated cell damage, without inducing CB1-mediated psychotropic effects (Baker et al., 2001; Cravatt et al., 2004; Gobbi et al., 2005; Kathuria et al., 20…”
BackgroundMoreira, F. A., Grieb, M., & Lutz, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.003 · Cited by 272
Bitencourt, R. M., Pamplona, F. A., & Takahashi, R. N. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.07.001 · Cited by 263
Mor, M., Rivara, S., Lodola, A., Plazzi, P. V., Tarzia, G., Duranti, A., Tontini, A., Piersanti, G., Kathuria, S., & Piomelli, D. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031140x · Cited by 276
Self-citationBachovchin, D. A., Ji, T., Li, W., Simon, G. M., Blankman, J. L., Adibekian, A., Hoover, H., Niessen, S., & Cravatt, B. F. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011663107 · Cited by 274
“Carbamates have been developed that show excellent selectivity for individual SHs and have proven valuable as research tools (22, 23, 25, 33) and therapeutic drugs (29).”
BackgroundMethodInfluentialThe neurobiology of individual differences in complex behavioral traits
Hariri, A. R. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.051508.135335 · Cited by 273
“In animal models, both pharmacologic and genetic disruption of FAAH function result in decreased anxiety-like behaviors, as well as increased consumption and preference for ethanol (Basavarajappa et al. 2006, Blednov et al. 2007, Kathuria et al. 2003, Moreira et al. 2008, Solinas et al. 2007).”
BackgroundDifferential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses
Busquets-Garcia, A., Puighermanal, E., Pastor, A., de la Torre, R., Maldonado, R., & Ozaita, A. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.022 · Cited by 273
Parsing the players: 2‐arachidonoylglycerol synthesis and degradation in the CNS
Murataeva, N., Straiker, A., & Mackie, K. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12411 · Cited by 251
“For example, FAAH knockout and FAAH inhibitors generally do not alter 2-AG levels (Lichtman et al., 2002; Kathuria et al., 2003; Schlosburg et al., 2010).”
BackgroundHariri, A. R., Gorka, A., Hyde, L. W., Kimak, M., Halder, I., Ducci, F., Ferrell, R. E., Goldman, D., & Manuck, S. B. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.10.047 · Cited by 248
“In animal models, increasing AEA signaling through pharmacologic or genetic disruption of FAAH has anxiolytic-like effects (23; 24).”
Turcotte, C., Chouinard, F., Lefebvre, J. S., & Flamand, N. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ru0115-021r · Cited by 243
“decreased coordination, are not observed [44, 66].”
The search for the palmitoylethanolamide receptor
LoVerme, J., La Rana, G., Russo, R., Calignano, A., & Piomelli, D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.05.012 · Cited by 248
“, 2002), and selective inhibitors that block its activity in vivo have been developed (Kathuria et al., 2003).”
BackgroundSelf-citation
Metadata
- Authors
- Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V., & Piomelli, D.
- Affiliations
- University of California, Irvine (US)
- University of Urbino (IT)
- University of Parma (IT)
- University of Naples Federico II (IT)
- University of Bari Aldo Moro (IT)
- Sapienza University of Rome (IT)
- Corresponding author
- Piomelli, Daniele
- ORCID
- Venue
- Nature Medicine
- Published
- 2002-12-02
- Volume
- 9
- Issue
- 1
- Pages
- 76-81
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4241363254
- Cited by
- 1,293
- References
- 45
- Citations by year
- 2026: 10 · 2025: 23 · 2024: 25 · 2023: 35 · 2022: 34 · 2021: 32 · 2020: 48 · 2019: 45 · 2018: 35 · 2017: 45 · 2016: 59 · 2015: 76 · 2014: 66 · 2013: 72 · 2012: 70
- FWCI
- 29.07
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Keywords
- anandamide, fatty acid amide hydrolase inhibition, anxiety, CB1 receptor, endocannabinoids, anxiolytics, benzodiazepine-like effects, elevated zero maze
- MeSH terms
- Rimonabant, Fatty Acid Amide Hydrolases, Amidohydrolases, Animals, Anxiety, Arachidonic Acids, Behavior, Animal, Cannabinoids, Cells, Cultured, Dose-Response Relationship, Drug, Humans, Neurons, Piperidines, Pyrazoles, Radioligand Assay, Receptors, Drug, Anti-Anxiety Agents, Vocalization, Animal, Molecular Structure, Rats, Wistar, Receptors, Cannabinoid, Rats, Polyunsaturated Alkamides, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.